AEterna Zentaris (AEterna Zentaris) Net Margin %

: -4,657.02% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. AEterna Zentaris's Net Income for the three months ended in Dec. 2023 was $-5.64 Mil. AEterna Zentaris's Revenue for the three months ended in Dec. 2023 was $0.12 Mil. Therefore, AEterna Zentaris's net margin for the quarter that ended in Dec. 2023 was -4,657.02%.

The historical rank and industry rank for AEterna Zentaris's Net Margin % or its related term are showing as below:

AEZS' s Net Margin % Range Over the Past 10 Years
Min: -146938.46 Med: -769.03 Max: 15.58
Current: -368.46

AEZS's Net Margin % is ranked worse than
60.53% of 1026 companies
in the Biotechnology industry
Industry Median: -163.69 vs AEZS: -368.46

AEterna Zentaris Net Margin % Historical Data

The historical data trend for AEterna Zentaris's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-1,135.71

-140.14

-159.09

-402.96

-367.99

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial															-501.05	-199.95	-112.11	-138,166.67	-4,657.02

Competitive Comparison

For the Biotechnology subindustry, AEterna Zentaris's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Net Margin % distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Net Margin % falls into.

AEterna Zentaris Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

AEterna Zentaris's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-16.552	/	4.498
	=	-367.99 %

AEterna Zentaris's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-5.635	/	0.121
	=	-4,657.02 %

AEterna Zentaris (NAS:AEZS) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

AEterna Zentaris Net Margin % Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.